Welcome to our dedicated page for Eupraxia Pharmaceuticals news (Ticker: $EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eupraxia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eupraxia Pharmaceuticals's position in the market.
Eupraxia Pharmaceuticals announced the expansion of its RESOLVE Phase 1b/2a trial for EP-104GI to treat eosinophilic esophagitis (EoE). Encouraging early-phase results with eight of nine patients responding positively and exhibiting good safety profiles spurred this decision. The expansion will allow for higher doses and longer follow-up periods, now up to 52 weeks. The study will include more participants, increasing from 12-15 to 27-33. Additional clinical sites will be established to support the new recruitment targets. The trial aims to gather data to support a potential registration trial in 2025.
Eupraxia Pharmaceuticals will host a virtual key opinion leader (KOL) event on May 29, 2024, at 10:00 AM ET to discuss their EP-104GI clinical development program for Eosinophilic Esophagitis (EoE). The event will feature Dr. Evan S. Dellon, a leading expert from the University of North Carolina, alongside company management. The focus will be on data from the Phase 1b/2a RESOLVE trial and the potential of Eupraxia's DiffuSphere™ technology to enhance treatment outcomes for EoE patients. A live Q&A session will follow.
Eupraxia Pharmaceuticals announced positive data from its Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE). Results from the first and second cohorts showed potential efficacy up to 24 weeks, with improved symptom outcomes and reduced eosinophil counts. The third cohort, receiving a higher dose, also reported symptom improvements at 12 weeks. The treatment demonstrated a strong safety profile with only mild to moderate adverse events. Eupraxia plans to continue data disclosure as the trial progresses.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announced that it will present initial results from its ongoing Phase 1b study of EP-104GI at the Digestive Disease Week (DDW) Annual Meeting 2024, held in Washington, D.C., from May 18-21, 2024.
The study focuses on treating eosinophilic esophagitis using EP-104GI, a long-acting injectable suspension of fluticasone propionate. Chief Scientific Officer Amanda Malone, PhD, will deliver a poster presentation on May 18, 2024.
The presentation details are: Abstract: 4031521, Session Type: Poster Session, Session Title: Eosinophilic Esophagitis and Gastroenteritis: Clinical, and Session Date & Time: May 18, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4).
Further details will be available on Eupraxia's website.
Eupraxia Pharmaceuticals reported its first quarter 2024 financial results and provided a corporate update, highlighting achievements such as listing on Nasdaq, progress in clinical studies, and financial performance. Notable milestones include the presentation of positive clinical data, initiation of Phase 3 development programs, and securing funding through public offerings. The company's focus on optimizing drug delivery technology and advancing treatments for conditions like osteoarthritis shows promise for future growth and development.
Eupraxia Pharmaceuticals has announced the formation of a Clinical Advisory Board for its gastrointestinal program, specifically focusing on the EoE treatment. The board consists of renowned experts in the field who will guide the development of EP-104GI for eosinophilic esophagitis. The company aims to address the unmet medical needs of the EoE patient population with their proprietary DiffuSphere™ technology.
